Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| PSP Pharma | Pharma | 6.8% | 30th pct | 110 |
| Impexpharm | Pharma | 6.3% | 26th pct | 110 |
| SmartPharm | Pharma | 5.4% | 23rd pct | 110 |
| Pharmaceutical House+ | Pharma | — | no FY data | 110 |
| Iberi + | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 3 of 5 peers filed FY2024. Switch to FY2021 (5 of 5).
| Line item | PSP Pharma | Impexpharm | SmartPharm | Pharmaceutical House+ | Iberi + |
|---|---|---|---|---|---|
| Total Current Assets | 392,371 | 50,341 | 14,872 | — | — |
| Total Non-Current Assets | 274,633 | 43,216 | 1,691 | — | — |
| TOTAL ASSETS | 667,004 | 93,557 | 16,563 | — | — |
| Total Current Liabilities | 248,714 | 14,987 | 3,483 | — | — |
| Total Non-Current Liabilities | 94,055 | 18,266 | 0 | — | — |
| TOTAL LIABILITIES | 342,769 | 33,253 | 3,483 | — | — |
| Total Equity | 324,235 | 60,304 | 13,080 | — | — |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | — | — |
| Total Debt | 112,540 | 18,266 | 0 | — | — |
| Cash & Equivalents | 20,687 | 3,447 | 1,279 | — | — |
| Net Debt | 91,853 | 14,819 | -1,279 | — | — |
Not every picked company reports every selected year — FY2024: no filing for Pharmaceutical House+ and Iberi +. Those cells are left blank (no filing), not zero.